| Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants |
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999. |
globenewswire.com |
2025-05-15 13:32:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants |
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-05-15 10:10:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights |
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 |
globenewswire.com |
2025-05-15 10:01:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Participate in Upcoming Investor Conferences |
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors |
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. |
globenewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript) |
Aura Biosciences, Inc (NASDAQ:AURA ) Virtual Urologic Oncology Investor Event Conference Call March 24, 2025 4:30 PM ET Company Participants Jill Hopkins - Chief Medical Officer & President of R&D Sabine Brookman-May - Senior Vice President, Therapeutic Area Head Urologic Oncology Joseph McQuaid - Clinical Lead, Urologic Oncology Jennifer Linehan - St. John's Cancer Institute Neal Shore - Carolina Urologic Research Center Gary Steinberg - Professor, Department of Urology at Rush University in Chicago Conference Call Participants Andy Berens - Leerink Philip Nadeau - TD Cowen Oliver McCammon - LifeSci Capital Jon Wolleben - JMP Securities George Farmer - Scotiabank Operator Good afternoon, and welcome to the Aura Biosciences Virtual Urologic Oncology Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Aura website following the conclusion of the event. |
seekingalpha.com |
2025-03-25 20:58:03 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights |
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential |
globenewswire.com |
2025-03-24 18:01:00 |
Czytaj oryginał (ang.) |
| Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress |
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect |
globenewswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress |
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology (EAU) Congress being held March 21-24, 2025, in Madrid, Spain. Aura will also participate in the EAU Research Forum during the Congress. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Participate in Upcoming Investor Conferences |
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen |
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. |
globenewswire.com |
2024-12-02 06:31:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value |
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer. |
seekingalpha.com |
2024-10-21 19:12:08 |
Czytaj oryginał (ang.) |
| Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease |
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC). |
benzinga.com |
2024-10-18 13:16:15 |
Czytaj oryginał (ang.) |
| Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial |
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors |
globenewswire.com |
2024-10-17 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Small-Cap Stocks Ready to Deliver Significant Growth |
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth. |
marketbeat.com |
2024-10-10 15:12:37 |
Czytaj oryginał (ang.) |
| Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + |
The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Qurate Retail's losses are mainly due to non-cash markdowns, making it a potential buy despite declining revenue and net income losses, according to Bashar Issa. RLJ Lodging Trust offers a 7.5% yield on their preferred stock, and Aristofanis Papadatos sees this as attractive for income-oriented investors as interest rates are expected to decline. |
seekingalpha.com |
2024-09-20 19:30:46 |
Czytaj oryginał (ang.) |
| Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company |
Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies. |
seekingalpha.com |
2024-09-17 16:31:46 |
Czytaj oryginał (ang.) |
| Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study |
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment. |
zacks.com |
2024-09-13 14:31:19 |
Czytaj oryginał (ang.) |
| Aura Biosciences Touts Promising Data From Eye Cancer Candidate |
Thursday, Aura Biosciences, Inc. AURA revealed Phase 2 end-of-study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and ocular cancer. |
benzinga.com |
2024-09-12 15:40:11 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma |
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer. |
globenewswire.com |
2024-09-12 10:30:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 |
Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology |
globenewswire.com |
2024-09-03 20:05:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Participate in Upcoming Investor Conferences |
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-28 20:05:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting |
Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 |
globenewswire.com |
2024-08-26 20:05:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights |
Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 |
globenewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? |
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-06-06 14:56:21 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Participate in the Jefferies Global Healthcare Conference |
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET. |
globenewswire.com |
2024-05-30 20:05:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 |
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, click here. |
globenewswire.com |
2024-05-23 12:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights |
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D. |
globenewswire.com |
2024-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences to Participate in Upcoming Investor Conferences |
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights |
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights. “We're excited to expand bel-sar into bladder cancer, as we leverage our therapy's unique mechanism of action in additional solid cancer indicati. |
businesswire.com |
2024-03-27 09:00:00 |
Czytaj oryginał (ang.) |